Table 3: Cohort study: Post-index differences by depression/anxiety.

 

 

Total

COPD with Depression/Anxiety

COPD without Depression/Anxiety

 

 

N

%

N

%

N

%

Difference,

P value

Number of Patients

31,279

100.00%

12,701

100.00%

18,578

100.00%

 

Drugs Post-Index (N, % with any fills)  

Antibiotics

15,913

50.87%

7,493

59.00%

8,420

45.32%

< 0.0001

ICS/LABA combination

6,110

19.53%

2,419

19.05%

3,691

19.87%

0.0718

Inhaled cortico-steroid (ICS)

2,118

6.77%

934

7.35%

1,184

6.37%

0.0007

Injected Steroids

96

0.31%

68

0.54%

28

0.15%

< 0.0001

Ipratropium

4,578

14.64%

2,165

17.05%

2,413

12.99%

< 0.0001

Long-acting beta-agonist (LABA)

719

2.30%

290

2.28%

429

2.31%

0.8807

Leukotriene Modifiers

2,817

9.01%

1,237

9.74%

1,580

8.50%

0.0002

Methylxanthines

1,216

3.89%

510

4.02%

706

3.80%

0.3335

Oral cortico-steroids (OCS)

6,294

20.12%

2,871

22.60%

3,423

18.43%

< 0.0001

Short-acting beta-agonist (SABA)

6,578

21.03%

2,907

22.89%

3,671

19.76%

< 0.0001

Tiotropium

4,470

14.29%

1,657

13.05%

2,813

15.14%

< 0.0001

any of above drugs*

23,103

73.86%

9,978

78.56%

13,125

70.65%

< 0.0001

Utilization (N, % with any event) 

Moderate Exacerbation

2,821

9.02%

1,396

10.99%

1,425

7.67%

< 0.0001

Severe Exacerbation

587

1.88%

318

2.50%

269

1.45%

< 0.0001

Utilization (Mean events, SD) 

Moderate Exacerbation

0.10

(0.31)

0.12

(0.34)

0.08

(0.29)

< 0.0001

Severe Exacerbation

0.02

(0.15)

0.03

(0.17)

0.02

(0.13)

< 0.0001

 

SD: standard deviation

*use of omalizumab and mast cell stabilizers are also included but not reported because of cell size report restrictions

p-values are calculated using chi-square test for frequency differences and t-test for mean differences